On construction sites, apprentice carpenters work side-by-side with journeyman pros. Now, CVS wants to take that same model to train pharmacy techs in Pennsylvania. In other states, pharmacy tech apprenticeship programs have reduced turnover, important in a tightening labor market.
The first digital pill offers a new way to monitor patients, but also raises privacy concerns.
Generic drug giant Mylan on Tuesday said it was expanding a previously announced restructuring plan aimed at streamlining its global operations.
The Chester County drug wholesaler is in "advanced settlement" talks with the Justice Department to resolve claims that oncology medicines were distributed to cancer patients by a manufacturer not registered with the FDA.
GlaxoSmithKline's shingles vaccine was voted the preferred prevention for the shingles virus for people 50 and older.
Merck will cut 1,800 sales jobs nationwide, but add 960 to a new 'chronic care' sales force. Merck does not know how many cuts will be local. Merck employs more than 12,000 in Pennsylvania, and is the largest private employer in Montgomery County.
In towns large and small, health officials have had to go begging for more money to cover the explosive growth of autopsies, toxicology tests, and overtime hours.
The Capitol Hill clash was set off by a provision in the annual defense authorization bill that would allow the secretary of defense to authorize the emergency use of drugs and devices that have not been approved by the Food and Drug Administration. The permission would apply to military personnel who...
Pharma firm with local ties to merge with N.J. generics drug maker, becoming the nation's fifth-largest generic drug business by revenue.
Gene therapy developed at Children's Hospital of Philadelphia gets a unanimous endorsement from FDA advisers to treat rare inherited blindness.
Spark Therapeutics will be questioned by a Food and Drug Administration panel this week about its gene therapy to treat a rare inherited blindness.
Analysis of a simple cheek swab can guide the choice of drugs for depression, anxiety, and ADHD. Revenues at Genomind have more than doubled, from $6.2 million in 2014 to $13.1 million in 2016.
Teva Pharmaceutical Industries gets a major blow: The FDA approves a rival company's generic version of Teva's top-selling multiple sclerosis medicine.